As systems become increasingly interconnected, we talk more and more about the importance of data and, more specifically, the need to get data to the right people, in the right format, at the right time, wherever they may be. This initiative has become even more...
As the landscape of pharmaceutical manufacturing has changed in the last few years, one exciting shift has a distinct possibility of being a game changer in coming decades. Regulatory agencies have increasingly begun to recognize the importance of automation...
There’s no question that today’s life sciences landscape is changing dramatically. As new personalized medicine solutions emerge, companies are rapidly changing scale to include more multi-product manufacturing facilities. Many of these facilities are manufacturing...
In this Emerson Automation Experts podcast, Michalle Adkins and Hilary Mills-Baker join me to discuss the challenges of achieving the required data integrity and solutions to drive performance improvements.
In a recent webinar, Achieve Data Integrity, Quality & Compliance Across Your Organization, Emerson’s Michalle Adkins and Hilary Mills-Baker share how data integrity means complete, consistent, accurate data throughout its lifecycle.
To know where you’re going, you have to know where you are, and operating a life sciences manufacturing facility is no exception. Pharmaceutical processors regularly have to take stock of their technological capacity to keep a finger on the pulse of the four main...
Emerson’s Michalle Adkins and AspenTech’s Chuck Miller team up to present Robust PAT Solutions to Support Process Development, Tech Transfer and Manufacturing at IFPAC 2023.
Recently, as cell and gene therapies have begun to emerge in the life sciences manufacturing landscape, an important concept has begun to draw attention: traceability. However, it is important to remember that traceability was critical long before today’s most...
People are more aware than ever of the many amazing ways new treatments can improve their lives. As a result, life sciences companies are under more pressure than ever to safely deliver new, innovative treatments to market to satisfy customer demand. The key to...
In just the last 10 years, biopharmaceutical supply chains have changed dramatically. The single-source manufacturing model is becoming much rarer, making way for multi-enterprise manufacturing collaborations and partnerships to better meet the changing needs of the...
There can be little question that Industry 4.0 technologies are reshaping the way life sciences companies operate. In the wake of the rapid development of vaccines during the COVID-19 pandemic, more facilities than ever are being “born digital.” Some of these...
On Monday at the Emerson Exchange Users’ Conference, Emerson’s Michalle Adkins and AbbVie’s Jeff Ziolkowski moderated a panel with Fujifilm’s Soren Skerris, Takeda’s Dr. Nina Schwalb, Eli Lilly’s James Weber, and Emerson’s Christian Berg. The experts shared the...
Our Global Community
Emerson Exchange 365
The opinions expressed here are the personal opinions of the authors. Content published here is not read or approved by Emerson before it is posted and does not necessarily represent the views and opinions of Emerson.